Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15,255 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
JCS/JSCS 2020 Guideline on Diagnosis and Management of Cardiovascular Sequelae in Kawasaki Disease.
Fukazawa R, Kobayashi J, Ayusawa M, Hamada H, Miura M, Mitani Y, Tsuda E, Nakajima H, Matsuura H, Ikeda K, Nishigaki K, Suzuki H, Takahashi K, Suda K, Kamiyama H, Onouchi Y, Kobayashi T, Yokoi H, Sakamoto K, Ochi M, Kitamura S, Hamaoka K, Senzaki H, Kimura T; Japanese Circulation Society Joint Working Group. Fukazawa R, et al. Among authors: suzuki h. Circ J. 2020 Jul 22;84(8):1348-1407. doi: 10.1253/circj.CJ-19-1094. Epub 2020 Jul 8. Circ J. 2020. PMID: 32641591 Free article. Review. No abstract available.
Revision of diagnostic guidelines for Kawasaki disease (6th revised edition).
Kobayashi T, Ayusawa M, Suzuki H, Abe J, Ito S, Kato T, Kamada M, Shiono J, Suda K, Tsuchiya K, Nakamura T, Nakamura Y, Nomura Y, Hamada H, Fukazawa R, Furuno K, Matsuura H, Matsubara T, Miura M, Takahashi K. Kobayashi T, et al. Among authors: suzuki h. Pediatr Int. 2020 Oct;62(10):1135-1138. doi: 10.1111/ped.14326. Epub 2020 Oct 1. Pediatr Int. 2020. PMID: 33001522 No abstract available.
Study protocol for a phase III multicentre, randomised, open-label, blinded-end point trial to evaluate the efficacy and safety of immunoglobulin plus cyclosporin A in patients with severe Kawasaki disease (KAICA Trial).
Aoyagi R, Hamada H, Sato Y, Suzuki H, Onouchi Y, Ebata R, Nagashima K, Terauchi M, Terai M, Hanaoka H, Hata A; KAICA Trial Investigators. Aoyagi R, et al. Among authors: suzuki h. BMJ Open. 2015 Dec 1;5(12):e009562. doi: 10.1136/bmjopen-2015-009562. BMJ Open. 2015. PMID: 26628527 Free PMC article. Clinical Trial.
Variations in ORAI1 Gene Associated with Kawasaki Disease.
Onouchi Y, Fukazawa R, Yamamura K, Suzuki H, Kakimoto N, Suenaga T, Takeuchi T, Hamada H, Honda T, Yasukawa K, Terai M, Ebata R, Higashi K, Saji T, Kemmotsu Y, Takatsuki S, Ouchi K, Kishi F, Yoshikawa T, Nagai T, Hamamoto K, Sato Y, Honda A, Kobayashi H, Sato J, Shibuta S, Miyawaki M, Oishi K, Yamaga H, Aoyagi N, Yoshiyama M, Miyashita R, Murata Y, Fujino A, Ozaki K, Kawasaki T, Abe J, Seki M, Kobayashi T, Arakawa H, Ogawa S, Hara T, Hata A, Tanaka T. Onouchi Y, et al. Among authors: suzuki h. PLoS One. 2016 Jan 20;11(1):e0145486. doi: 10.1371/journal.pone.0145486. eCollection 2016. PLoS One. 2016. PMID: 26789410 Free PMC article.
Efficacy of primary treatment with immunoglobulin plus ciclosporin for prevention of coronary artery abnormalities in patients with Kawasaki disease predicted to be at increased risk of non-response to intravenous immunoglobulin (KAICA): a randomised controlled, open-label, blinded-endpoints, phase 3 trial.
Hamada H, Suzuki H, Onouchi Y, Ebata R, Terai M, Fuse S, Okajima Y, Kurotobi S, Hirai K, Soga T, Ishiguchi Y, Okuma Y, Takada N, Yanai M, Sato J, Nakayashiro M, Ayusawa M, Yamamoto E, Nomura Y, Hashimura Y, Ouchi K, Masuda H, Takatsuki S, Hirono K, Ariga T, Higaki T, Otsuki A, Terauchi M, Aoyagi R, Sato T, Fujii Y, Fujiwara T, Hanaoka H, Hata A; KAICA trial Investigators. Hamada H, et al. Among authors: suzuki h. Lancet. 2019 Mar 16;393(10176):1128-1137. doi: 10.1016/S0140-6736(18)32003-8. Epub 2019 Mar 7. Lancet. 2019. PMID: 30853151 Clinical Trial.
Cyclosporin A treatment for Kawasaki disease refractory to initial and additional intravenous immunoglobulin.
Suzuki H, Terai M, Hamada H, Honda T, Suenaga T, Takeuchi T, Yoshikawa N, Shibuta S, Miyawaki M, Oishi K, Yamaga H, Aoyagi N, Iwahashi S, Miyashita R, Onouchi Y, Sasago K, Suzuki Y, Hata A. Suzuki H, et al. Among authors: suzuki y. Pediatr Infect Dis J. 2011 Oct;30(10):871-6. doi: 10.1097/INF.0b013e318220c3cf. Pediatr Infect Dis J. 2011. PMID: 21587094
Association of an IGHV3-66 gene variant with Kawasaki disease.
Johnson TA, Mashimo Y, Wu JY, Yoon D, Hata A, Kubo M, Takahashi A, Tsunoda T, Ozaki K, Tanaka T, Ito K, Suzuki H, Hamada H, Kobayashi T, Hara T, Chen CH, Lee YC, Liu YM, Chang LC, Chang CP, Hong YM, Jang GY, Yun SW, Yu JJ, Lee KY, Kim JJ, Park T; Korean Kawasaki Disease Genetics Consortium, Taiwan Kawasaki Disease Genetics Consortium, Taiwan Pediatric ID Alliance, Japan Kawasaki Disease Genome Consortium; Lee JK, Chen YT, Onouchi Y. Johnson TA, et al. Among authors: suzuki h. J Hum Genet. 2021 May;66(5):475-489. doi: 10.1038/s10038-020-00864-z. Epub 2020 Oct 26. J Hum Genet. 2021. PMID: 33106546 Free PMC article.
15,255 results
You have reached the last available page of results. Please see the User Guide for more information.